AstraZeneca is one of the most appreciated and, at the same time, criticised vaccines against Covid19. The first half of 2021 has proved to be influential against variants. Vaccine sales have hit $1.2 billion. The University of Oxford has contributed to the advancement of the jab.
The group has exported 319 million doses. Making a profit is not the prime motive but circulating it as much as possible is the objective.
Criticism faced by this was revolving around the blood clots. Several patients suffered from blood clotting after getting vaccinated. Safety doubts were lifted and suspensions occurred in some European nations. Vaccine sales tripled in the three months. The robust elevation was witnessed from 275 million US dollars to 894 million US dollars.
Chief Executive, Pascal Soriot asserted that “We have made dramatic progress with our Covid-19 vaccine Vaxzevria,” he further said, “As of today, AstraZeneca and our partners have released one billion doses to more than 170 countries.”
Winning the trust of these many countries and resolving the issue of rare clots has proved to be a success for Astrazeneca.
The development program did ensure authenticity included a phase three trial of 30000 partakers. Recently, 65.5 million pounds were declared openly by the British government as fresh funding for enhancing the quality of vaccines.
Nations are investing lots of money just to defend the third wave. But, due to various issues like production issues, data didagreements, etc. vaccine is struggling to prove its credibility.
The US has said ‘No’ to vaccines. On Thursday, Astrazeneca will approach the US for approval. The Philippines will get 4,15,000 doses of vaccine from the UK.
On Wednesday, UK Foreign Secretary Dominic Raab said, “This is part of the first batch of the 100 million doses we’ve pledged to get the poorest parts of the world vaccinated as a matter of urgency.”
Controversy is about to fade away like a night & The sunrise of a healthy world will take place.